Bill Ackman's Pershing Square Down 19% YTD (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Valeant (VRX) PT, Estimates Cut at BMO Capital; Remains on the Sidelines
November 3, 2015 8:18 AM ESTBMO Capital analyst Alex Arfaei cut estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $133.00 (from $141.00). The firm is also staying on the sidelines with a Market Perform rating amid news the company is terminating its relationship with Philidor.
Arfaei commented, "Although we welcome this course of action, we... More
Valeant Pharma (VRX) Adds to Gains
November 3, 2015 8:14 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is adding to yesterday's gains in pre-open trade. Shares are up 5.8% to $106.28 after rising 7.15% yesterday. Shares have been under extreme pressure as short sellers point to fraud at the company and regulators point to 'price... More
Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI
November 2, 2015 9:04 PM ESTEvercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.
Raffat highlighted the following from the letter:
For... MoreMarket Wrap: Dow Jones Turns Positive for 2015; Citron Out with More on Valeant; Mergers Galore
November 2, 2015 5:44 PM ESTMarket wrap for November 2nd
End of the Day: S&P 500 up 24.7 to 2,104.05; Dow Jones up 165.2 to 17,828.76; Nasdaq up 73.4 to 5,127.15
Market Brief: The Dow Jones Industrial Average pushed into positive territory for 2015, now up a modest 0.03% for the year.
Energy stocks made a 2.4 percent move higher today, leading the S&P 500.
Merger Monday is back for the second-straight week as a slew of announcements were made ahead of the opening bell.
Citron Research was... More
Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?
November 2, 2015 3:17 PM ESTCitron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
Valeant Pharma (VRX) Was Top Stock for TD Ameritrade Retail Clients on Friday - Sherrod
November 2, 2015 2:03 PM ESTValeant Pharma (NYSE: VRX) was the most heavily traded stock for TD Ameritrade retail investors on Friday, Nicole Sherrod said. Buys heavily outweighed sells.
$VRX was the #1 top traded stock for TD Ameritrade retail investors on Friday. Buys heavily outweighing sells.
Nicole Sherrod (@TDANSherrod) November 2, 2015... MoreGoldman Sachs says Valeant has long road ahead, cuts rating
November 2, 2015 1:19 PM ESTBy Ankur Banerjee
(Reuters) - Goldman Sachs on Monday downgraded Valeant Pharmaceuticals International Inc's (NYSE: VRX) (NYSE: VRX) stock, nearly two weeks after an influential short seller accused the Canadian drug maker of cooking its books.
While investors have fled the company's stock, which has lost a third of its value since Citron Research published its report on Oct. 21, sell-side analysts have remained stubbornly positive on the stock.
BTIG and BMO Capital Markets have lowered their ratings to "hold" in the past two weeks.... More
Citron's Andrew Left said he is not done with Valeant (VRX) story; Will pass info to main stream media
November 2, 2015 12:28 PM ESTCitron's Andrew Left said he is not done with Valeant (NYSE: VRX) story. Will pass info to main stream media.
... MoreCitron's Andrew Left denies he made $150 million short Valeant (VRX)
November 2, 2015 12:25 PM ESTCitron's Andrew Left denies he made $150 million short Valeant (NYSE: VRX).
... MoreCitron's Left stands by story on Valeant (VRX)
November 2, 2015 12:25 PM ESTCitron's Left stands by story on Valeant (NYSE: VRX)
... MoreCitron's Left said "I have nothing with Bill Ackman. This is about Valeant (VRX)"
November 2, 2015 12:18 PM ESTCitron's Left said "I have nothing with Bill Ackman. This is about Valeant (NYSE: VRX)."
... More